Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Integra Looks Ahead To Adhesion Barrier Application For DuraGen Matrix

This article was originally published in The Gray Sheet

Executive Summary

Integra LifeSciences intends to begin a U.S. multi-site clinical trial in the second half of this year to evaluate DuraGen Plus matrix as a barrier to adhesion following spinal and cranial surgery

You may also be interested in...



Integra Acquisition Strategy Boosts Q2 Sales, Clouds Organic Growth Rate

Integra LifeSciences will continue to pursue potential acquisitions after completing four deals so far this year

Integra Acquisition Strategy Boosts Q2 Sales, Clouds Organic Growth Rate

Integra LifeSciences will continue to pursue potential acquisitions after completing four deals so far this year

CIBC World Markets Healthcare Conference In Brief

Integra finds Newdeal for foot repair: Acquisition of French reconstructive surgery device maker Newdeal for $50 mil. Nov. 14 adds specialty implants and instruments for foot and angle surgery. Key offerings include Bold screws, Hallu-Fix plates and Hintegra total ankle prostheses sold through direct reps in France, Belgium and the Netherlands, as well as distributors in the U.S. and other countries. Newdeal sales totaled about $18 mil. in 2003. Integra expects the devices to dovetail with its own regenerative offerings, including Integra dermal regeneration templates and wound dressings, and NeuraGen and NeuraWrap nerve repair products - which can be used to treat foot and ankle wounds. During a Nov. 9 session of the CIBC meeting in New York, Integra CEO Stuart Essig noted that the firm's peripheral nerve injury offerings were "growing quickly," aided by the September launch of the 510(k)-cleared NeuraWrap collagen nerve repair conduit for injured, compressed or scarred nerves. The line includes NeuraGen, launched in 2001 for completely severed nerves...

Related Content

UsernamePublicRestriction

Register

MT021807

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel